Skip to main content
Terug
WLCGF logo

Welcia Holdings Co., Ltd.

Datakwaliteit: 100%
Overbought
WLCGF
OTC Healthcare Medical - Pharmaceuticals
€ 16,41
€ 0,00 (0,00%)
Marktkapitalisatie: 3,42B
Dagbereik
€ 16,41 € 16,41
52-Weeksbereik
€ 16,41 € 16,41
Volume
153
50D / 200D Gem.
€ 16,41 / € 16,41
Vorige Slotkoers
€ 16,41

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,2 0,4
P/B 0,0 2,9
ROE % 6,2 3,7
Net Margin % 1,2 3,8
Rev Growth 5Y % 7,9 10,0
D/E 0,3 0,2

Belangrijkste Punten

Revenue grew 7,85% annually over 5 years — modest growth
Earnings declined -43,45% over the past year
Debt/Equity of 0,33 — conservative balance sheet
Generating 35,35B in free cash flow
P/E of 0,23 — trading at a low valuation
Cash machine — converts 236,35% of earnings into free cash flow

Groei

Revenue Growth (5Y)
7,85%
Revenue (1Y)5,56%
Earnings (1Y)-43,45%
FCF Growth (3Y)-6,56%

Kwaliteit

Return on Equity
6,15%
ROIC8,28%
Net Margin1,16%
Op. Margin2,83%

Veiligheid

Debt / Equity
0,33
Current Ratio1,19
Interest Coverage46,38

Waardering

P/E Ratio
0,23
P/B Ratio0,01
EV/EBITDA1,36
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5,56% Revenue Growth (3Y) 5,97%
Earnings Growth (1Y) -43,45% Earnings Growth (3Y) -25,61%
Revenue Growth (5Y) 7,85% Earnings Growth (5Y) -14,51%
Profitability
Revenue (TTM) 1,29T Net Income (TTM) 14,96B
ROE 6,15% ROA 2,58%
Gross Margin 30,38% Operating Margin 2,83%
Net Margin 1,16% Free Cash Flow (TTM) 35,35B
ROIC 8,28% FCF Growth (3Y) -6,56%
Safety
Debt / Equity 0,33 Current Ratio 1,19
Interest Coverage 46,38 Dividend Yield 0,01%
Valuation
P/E Ratio 0,23 P/B Ratio 0,01
P/S Ratio 0,00 PEG Ratio -0,79
EV/EBITDA 1,36 Dividend Yield 0,01%
Market Cap 3,42B Enterprise Value 49,65B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,29T 1,22T 1,14T 1,03T 949,65B
Net Income 14,96B 26,45B 27,03B 26,45B 28,00B
EPS (Diluted) 72,18 127,75 129,29 126,98 134,10
Gross Profit 390,36B 370,11B 326,34B 302,26B 279,36B
Operating Income 36,41B 43,23B 45,64B 43,02B 42,98B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 579,99B 551,86B 537,36B 463,05B 435,69B
Total Liabilities 325,50B 307,50B 304,97B 255,16B 255,33B
Shareholders' Equity 248,61B 237,71B 225,91B 201,79B 179,72B
Total Debt 81,25B 82,70B 86,07B 62,51B 47,71B
Cash & Equivalents 35,01B 30,53B 32,31B 22,84B 50,94B
Current Assets 280,89B 259,60B 242,70B 208,00B 215,89B
Current Liabilities 236,62B 222,48B 216,63B 189,02B 203,05B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#106 of 1024
69
Custom Deep Value Investing (Seth Klarman)
#191 of 820
57
Value Defensive Investing (Benjamin Graham)
#402 of 708
25

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026